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Background: We aimed to identify prognostic blood biomarkers using proteomics-based approaches in malignant pleural
mesothelioma (MPM).
Methods: Plasma samples from 12 MPM patients were used for exploratory mass spectrometry and ELISA analyses. The
significance of secreted protein acidic and rich in cysteine (SPARC) was examined in sera from a Dutch series (n¼ 97). To
determine the source of the circulating SPARC, we investigated SPARC expression in MPM tumours and healthy controls, as well
as the expression and secretion from cell lines and xenografts.
Results: Secreted protein acidic and rich in cysteine was identified as a putative prognostic marker in plasma. Validation in the
Dutch series showed that the median survival was higher in patients with low SPARC compared with those with high SPARC (19.0
vs 8.8 months; P¼ 0.01). In multivariate analyses, serum SPARC remained as an independent predictor (HR 1.55; P¼ 0.05). In MPM
tumour samples, SPARC was present in the tumour cells and stromal fibroblasts. Cellular SPARC expression was higher in 5 out of
7 cell lines compared with two immortalized mesothelial lines. Neither cell lines nor xenograft tumours secreted detectable
SPARC.
Conclusions: Low circulating SPARC was associated with favourable prognosis. Secreted protein acidic and rich in cysteine was
present in both tumour cells and stromal fibroblasts; and our in vitro and in vivo experiments suggest that stromal fibroblasts are a
potential source of circulating SPARC.
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Malignant pleural mesothelioma (MPM) is an almost invariably
fatal, asbestos-related malignancy arising from the mesothelium
surrounding the thoracic cavities. Progress in MPM treatment has
remained modest, with a median survival varying from 7 months
to 2 years (Vogelzang, 2008; Van Meerbeeck et al, 2011). Use of the
few treatment options available is guided by traditional prognostic
factors such as performance status, histological subtype and stage
of disease (Scherpereel et al, 2010; Van Meerbeeck et al, 2011). The
use of pemetrexed/cisplatin chemotherapy is associated with a
response rate of around 40% and a survival gain of around 3
months (Vogelzang et al, 2003). None of the molecular markers
investigated to date is able to accurately predict the course of the
disease or the response to therapy. A biomarker, or a combination
of biomarkers, that is able to determine prognosis or response to
therapy and which is accurate enough to be used for the selection
of individual patients is therefore urgently needed. Ideally, a simple
blood-based biomarker would be advantageous given its easy
accessibility.
There are several blood-based biomarkers that have been shown
to have some diagnostic utilities. These include osteopontin,
soluble mesothelin-related peptides (SMRP) and more recently,
fibulin-3 (Grigoriu et al, 2007; Roe et al, 2008; Schneider et al,
2008; Pass et al, 2012). These diagnostic biomarkers also have a
limited prognostic role in MPM, with elevated levels of osteopontin
and SMRP showing correlation with shorter survival (Grigoriu
et al, 2007; Roe et al, 2008; Schneider et al, 2008). Although the
concentration of fibulin-3 in the plasma did not correlate with
survival, high levels in effusions were associated with shorter
survival (Pass et al, 2012).
Identification of circulating blood-based biomarkers has also
been attempted via proteomics-based approaches. Ostroff et al
(2012) discovered and validated a panel of serum biomarkers as a
non-invasive proteomics-based surveillance tool in the early
diagnosis of MPM in patients at high risk for this disease. Using
the Selected Reaction Monitoring (SRM) assay technology,
Cerciello et al (2013) also identified serum protein-derived
candidate biomarker panels for the diagnosis of MPM.
Given the feasibility of biomarker identification using proteo-
mics-based technology and the lack of accurate prognostic
biomarkers in MPM, we initially designed an exploratory
proteomic study, in which we systematically investigated proteins
present in plasma of MPM patients using the isobaric tag for
relative and absolute quantification (iTRAQ) mass spectrometry
(Ross et al, 2004). This identified secreted protein acidic and rich in
cysteine (SPARC; or osteonectin) as a promising prognostic
biomarker. Further investigation suggested that circulating levels
of SPARC appear to originate from the stroma.
MATERIALS AND METHODS
Patients and clinical materials. Three retrospective series of
MPM patients were included in this study. The discovery series
consisted of 12 patients from the parallel, non-randomized phase II
studies investigating the effectiveness of thalidomide (arm A:
thalidomide in combination with cisplatin and gemcitabine
[n¼ 34]; and arm B: thalidomide alone [n¼ 29], recruited between
April 2001 and August 2003) (Kao et al, 2012) consisting of the six
shortest and six longest surviving patients (median overall survival
[OS] 1.2 and 38.3 months, respectively; Supplementary Table 1 for
patient characteristics). This sample set was used to identify
circulating biomarkers associated with OS differences. Overall
survival was defined as the time from enrolment to death, while
progression-free survival (PFS) was defined as the time from
enrolment to progression (or death if progression had not
occurred). Collected blood was centrifuged at 2500 g for 10min,
and separated plasma was stored at  80 1C. Patients gave written
informed consent under the protocol approved by the Human
Research Ethics Committee (HREC) at Royal North Shore Hospital.
The second series consisted of 97 pathologically confirmed
MPM patients treated at the Netherlands Cancer Institute between
1995 and 2011. Patients donated blood samples at the time of
diagnosis, which were spun at 3100 r.p.m. for 10min to isolate
serum, which was then stored at  30 1C. This series was used for
validation of candidate circulating protein biomarkers, which is the
primary analysis in this study. Overall survival was defined as
the time from diagnosis to death. Patients gave consent under the
Institutional Biobank Programme approved by HREC at the
Antoni van Leeuwenhoek Hospital-Netherlands Cancer Institute.
The third series consisted of archival tumour samples from 74
MPM patients treated with palliative pleurectomy±decortication
(P/D) at Royal Prince Alfred Hospital (RPAH), Sydney between
1991 and 2009. Overall survival in this series was defined as the
time from the surgical procedure to death. These formalin-fixed
paraffin-embedded (FFPE) samples were used to examine tumour
SPARC expression. Waiver of consent was approved by HREC at
Sydney Local Health District (SLHD) due to the retrospective
nature of the series.
Normal mesothelium (n¼ 13) was used as a control with the
third series and consisted of patients without a history of
malignancy or inflammatory conditions who underwent cardiac
or aortic surgery at RPAH. Patients gave written informed consent,
and the collection of normal mesothelium was approved by HREC
at SLHD.
iTRAQ. Patient plasma samples from the first series were immuno-
depleted of the top 14 most abundant plasma proteins using a multiple
affinity removal system (Agilent Technologies, Santa Clara, CA, USA)
following the manufacturer’s direction. The unbound fraction was
collected and precipitated in ice-cold acetone overnight. The sample
was centrifuged at 14000g for 10min to pellet the proteins. The
acetone was decanted and pellet resuspended with 0.1M triethylam-
monium bicarbonate before labelling for iTRAQ analysis. A common
reference sample consisting of a pool of all samples was used in each
iTRAQ experiment as the denominator for determining ratios. Samples
were labelled by following the manufacturer’s protocol with modifica-
tions as previously described (Song et al, 2008). Tryptic peptides were
fractionated by strong cation exchange chromatography then each
fraction analysed by information-dependent acquisition using reversed-
phase nanoLC/MS using a TripleTOF 5600 mass spectrometer
(ABSciex, Framingham, MA, USA). Data files were searched against
the Human SWISS-PROT protein database using ProteinPilot (v4.0,
ABSciex) with thorough search mode and bias correction.
Proteins were assigned with a false discovery rate ofo1%. Differential
expression of proteins measured by iTRAQ between short- and
long-MPM survivors was assessed using an empirical Bayes moderated
t-test as implemented in the limma library from Bioconductor
(Gentleman et al, 2004), as we have previously described (Jankova
et al, 2011). A test P-value of p0.05 was regarded as evidence of
differential abundance.
ELISA. The protein candidates were validated by quantification
using commercially available ELISA kits in accordance with the
manufacturers’ instruction, carried out by researchers blinded to
the study endpoint. These included Selenoprotein P (qy-e01007;
Qayee-Bio for Life Science, Shanghai, China), Tetranectin
(E80350Hu; Uscn Life Science Inc, Wuhan, China) and SPARC
(E90791Hu; Uscn Life Science Inc). Duplicate measures were made
for each sample.
Protein levels were calculated and expressed as either mgml 1
(Selenoprotein P, Tetranectin and SPARC in plasma and serum) or
ng per total protein (SPARC in cell lysates and cell-conditioned
medium).
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Tissue microarrays. Formalin-fixed paraffin-embedded tumour
tissue blocks from the P/D procedure and normal mesothelium blocks
from cardiac surgery were retrieved. Areas containing tumour and
normal mesothelium, respectively, were marked on the haemotoxylin
and eosin slides; and the corresponding areas were determined on the
FFPE blocks. Tissue microarrays (TMAs) were constructed as described
previously (Kao et al, 2011). Briefly, a minimum of four 1-mm cores
were sampled from the FFPE blocks and inserted into a recipient block,
using the ATA-100 Advanced Tissue Arrayer (Chemicon, Temecula,
CA, USA). Cores of smooth muscle were included as negative controls
in each TMA (Supplementary Figure 1).
Immunohistochemistry. Serial 4-mm paraffin sections of the TMA
blocks underwent immunohistochemical staining for SPARC.
Sections were incubated with primary rabbit polyclonal anti-SPARC
antibody (AB14174, dilution 1 : 1000; Abcam, Boston, MA, USA) for
32min at room temperature after using CC2 (Ventana Medical
Systems, Tucson, AZ, USA) as an antigen retrieval solution (citrate
buffer pH 6) for 44min at 97 1C. The reaction was developed with
the UltraView DAB detection kit (Ventana Medical Systems), using
BenchMark ULTRA (Ventana Medical Systems).
Immunostaining evaluation. Immunostaining was assessed by an
expert pulmonary pathologist (WAC) who was blinded to the
clinical data. Positive labelling was defined as cells with cytoplasmic
staining of any intensity. The percentage of cells labelled by the
antibodies (0–100%) was recorded in all assessable cores in a semi-
quantitative manner. Separate scores were determined for both the
tumour cells and the stromal fibroblasts. The final score for SPARC
staining in samples from each patient was calculated from the
average score of the available cores in the TMAs.
Cell lines: cell-conditioned medium and protein lysates. Five
human mesothelioma cell lines (H28, H226, H2452 and MSTO)
and the immortalized mesothelial cell line MeT-5A were obtained
from the American Type Culture Collection (Manassas, VA, USA;
it should be noted here that although listed as mesothelioma by
ATCC, it has been debated whether the origin of the NCI-H226
cell line was a mesothelioma or a pleural metastasis from a
squamous cell carcinoma of the lung). In addition, the previously
described MPM lines MM05 (Relan et al, 2013), VMC23 (Kryeziu
et al, 2013) and SPC111 (Schmitter et al, 1992) and the mesothelial
line LP9 (Wu et al, 1982) were included. Cell lines were grown in
their corresponding medium (RPMI-1640 for all MPM lines,
DMEM for MeT-5A, M199 supplemented with 3.3 nM EGF, 400 nM
hydrocortisone and 1% insulin-transferrin-selenium for LP9)
supplemented with 10% fetal bovine serum (FBS) at 37 1C, 5%
CO2 and 95% humidity. All media and supplements were
purchased from Life Technologies (Carlsbad, CA, USA) or
Sigma-Aldrich (St Louis, MO, USA).
To obtain cell-conditioned medium, cells were grown to 80%
confluence in T25 flasks in medium containing FBS, before
medium was replaced with 2ml serum-free medium. Cell-
conditioned medium was collected after 24 h, cell debris removed
by 5min centrifugation at 1200 r.p.m., and supernatants stored at
 80 1C. Protein lysates were prepared from the same cells by lysis
in 300 ml RIPA buffer as described previously (Linton et al, 2014).
Protein concentration was determined using the Pierce BCA
Protein Assay Kit (Thermo Scientific, Waltham, MA, USA)
according to the manufacturer’s instructions.
Mouse plasma and serum samples. Athymic (nu/nu) mice were
purchased from the Animal Resources Centre (Perth, WA,
Australia) and injected subcutaneously in the left flank with
5 106 H226 or 3 106 MSTO cells in 100 ml serum-free medium/
growth factor-reduced matrigel mix (1 : 1, matrigel from BD
Biosciences, Franklin Lakes, NJ, USA). Once tumours reached
around 300mm3, mice were killed and blood was collected via
cardiac puncture into either empty or EDTA-containing tubes.
Serum samples were allowed to clot for 60min at room
temperature before being further processed as for plasma samples
(centrifugation at 2500 r.p.m. for 20min), and both were stored at
 80 1C. Animal studies were approved by the SLHD Animal
Welfare Committee.
Statistical analysis. The primary end point of the study was OS,
with definitions stated above. The primary analysis was the
validation of circulating SPARC in the Dutch series. Validation of
ELISA protein quantification in plasma and serum was performed
using the median protein level as a cutoff, to define the two groups
of patients (protein-high vs protein-low). This was defined a priori.
The comparison of the baseline patient characteristics and
survival in all patient cohorts was made using IBM SPSS Statistics,
Version 19 (SPSS Inc, Chicago, IL, USA): chi-square test for
categorical variables; Log-rank test for Kaplan–Meier survival
analysis; and Mann–Whitney U-test for non-parametric distribu-
tion comparison. For the primary analysis of determination of
prognostic value of circulating SPARC, multivariate analysis was
performed using the Cox proportional hazards regression model
incorporating age, gender, stage, histological subtype and circulat-
ing SPARC level (SPARC-high vs SPARC-low).
To determine the association of SPARC protein expression in
the tumour samples with the clinical characteristics (such as age,
gender and histological subtype), we used chi-squared test.
Significant variables in the univariate analyses were entered into
a logistic regression model without selection; and the results of the
logistic regression modelling are presented as odds ratios (ORs)
and associated 95% confidence interval (CIs). A P-value of p0.05
was considered as statistically significant.
RESULTS
Circulating SPARC has prognostic value in MPM. The 12
patients from series one were used for exploratory proteomic analyses.
The total number of proteins identified was 226. The iTRAQ analysis
of the samples from the short and long survivors revealed five plasma
proteins that showed a statistically significant difference (Po0.05) in
abundance. Selenoprotein P and tetranectin were elevated in long-
term survivors, while insulin-like growth factor-binding protein 2
(IBP2), platelet basic protein (CXCL7) and SPARC were found to be
reduced in plasma of long-term survivors (Supplementary Table 2).
Further quantification by ELISA was performed for selenoprotein P,
tetranectin and SPARC (Supplementary Table 3). Median protein
levels were used to divide the 12 patients into protein-high vs protein-
low for the individual proteins examined. Using the Kaplan–Meier
method, SPARC was the only protein that differentiated the patient
OS. Low level of SPARC was associated with long survival (median
OS: 32.1 vs 1.2 months for low vs high SPARC; P¼ 0.006). Box plots
are shown in Supplementary Figure 2 to demonstrate the differential
abundance of SPARC.
To validate the association between SPARC and OS, SPARC
levels were measured in samples from 97 patients from series two
(patient characteristics are described in Table 1). At the time of the
report, 92 patients were deceased. The median age of the patients
was 60 years (range: 42–76 years), and the median OS was 13.5
months (95% confidence interval [CI]: 9.3–17.8 months). The
median SPARC concentration measured by ELISA was
1.75 mgml 1 (range: 0.55–2.76 mgml 1; standard deviation [s.d.]
0.41 mgml 1) in this series and was used to categorise patients into
SPARC-high and SPARC-low groups. The median OS was
significantly higher in patients with SPARC-low (19.0 months;
95% CI: 12.1–25.9 months) compared with SPARC-high patients
(8.8 months; 95% CI: 7.8–9.9 months, P¼ 0.01; Figure 1A). The
median OS was higher in female (14.7 months; 95% CI: 0–30.7)
compared with male gender (10.7 months; 95% CI: 6.6–14.8
BRITISH JOURNAL OF CANCER SPARC in mesothelioma
526 www.bjcancer.com |DOI:10.1038/bjc.2015.470
months; P¼ 0.03; Figure 1B). In contrast, OS did not differ
significantly for age (median OS: 13.1 vs 13.0 for age o60 years
and X60 years respectively; P¼ 0.60), histological subtype
(median OS: 13.7 vs 8.8 months for epithelial and non-epithelial
histological subtype; P¼ 0.15) and stage (median OS: 17.0 vs 10.1
months for stages I–II and III–IV respectively; P¼ 0.14). Using the
multivariate Cox proportional hazard Regression model, incorpor-
ating all the above factors, SPARC remained an independent
prognostic factor, with low SPARC level being associated with
longer survival (HR: 1.55; P¼ 0.05; Table 2).
SPARC is overexpressed in MPM tumours. To determine the
potential source of circulating SPARC, we first examined the
SPARC protein expression in TMAs generated from archival MPM
tumour samples from 74 patients who underwent P/D (series
three). Owing to attrition of assessable cores, 72 patients were
analysed for tumoral SPARC expression while 69 patients were
analysed for stromal fibroblast expression, with 13 samples from
normal pleural mesothelium from patients undergoing cardiac or
aortic surgery used as controls. Cytoplasmic labelling of SPARC
was found in all histological subtypes of MPM with staining in
both the tumour cells and the stromal fibroblasts (Figure 2A and B).
We found both the SPARC IHC scores to be significantly
higher in MPM tumour cells (P¼ 0.001) and MPM stromal
fibroblasts (Po0.001) compared with respective scores in the
normal mesothelium (Figure 2C and D). The SPARC protein in the
tumour cells tended to be universally expressed (median expression
100%; range 0–100%), while SPARC in the stromal fibroblasts was
more heterogeneous (median expression 50%; range 0–100%). The
box plots in Figure 2C and D demonstrate the distribution of the
SPARC expression in these P/D patients.
Table 3 illustrates that stromal expression of SPARC protein was
associated with non-epithelial subtype of MPM. Using logistic
regression, high stromal SPARC expression (450%) remained
independently associated with non-epithelial subtype (OR: 7.7;
95% CI: 2.3–26.2; P¼ 0.001). In contrast, SPARC protein tumoral
expression was not associated with histological subtype (P¼ 1.00)
but female patients were significantly more likely to have SPARC
expression in the tumour cells (P¼ 0.02; Table 3). In addition, low
stromal SPARC (p50%) was associated with longer survival (10.9
vs 7.6 months; P¼ 0.001; Figure 2E) while there was no association
between tumoral SPARC and patient survival (P¼ 0.71). In
contrast, in a multivariate Cox proportional hazard regression
model (n¼ 69) incorporating stromal SPARC, age, gender and
histological subtype, histological subtype remained an independent
predictor of prognosis (HR: 2.47; 95% CI: 1.38–4.44; P¼ 0.002),
while stromal SPARC did not (HR: 1.42; 95% CI: 0.76–2.63;
P¼ 0.27). This is likely to be a result of the strong association
between histological subtype and stromal SPARC expression.
Table 1. Baseline characteristics for the series of patients
from the Netherlands (series two, n¼97)
No. (%)
Patient characteristics Total
SPARC-
low
SPARC-
high P-value
Age
o60 years 47 (48%) 22 25
0.91
X60 years 50 (52%) 24 26
Gender
Male 82 (85%) 38 44
0.62Female 15 (15%) 8 7
Stage
I 37 (38%) 18 19
II 10 (11%) 4 6
III 22 (23%) 8 14 0.24
IV 12 (12%) 5 7
Unknown 15 (16%) 11 4
Histological subtype
Epithelioid 73 (75%) 32 41
0.13Biphasic 12 (13%) 9 3
Sarcomatoid 11 (11%) 4 7
Unknown 1 (1%) 1 0
Treatment received
Chemotherapy 65 (67%) 29 36 0.62
Radical surgery 21 (22%) 11 10 0.57
Supportive care alone 17 (18%) 7 10 0.57
Abbreviation: SPARC, secreted protein acidic and rich in cysteine.
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Figure 1. Kaplan–Meier curves for the patients in series two according to serum SPARC (A) and gender (B).
Table 2. Multivariate analysis of association of baseline
prognostic factors with overall survival in patients from the
Netherlands (series two; n¼97)
Factor HR 95% CI P-value
Age
o60 years Reference
0.346
X60 years 1.25 0.79–1.99
Gender
Female Reference
0.049
Male 1.85 1.00–3.40
Stage
I–II Reference
0.047
III–IV 1.61 1.00–2.58
Histological subtype
Epithelioid Reference
0.238
Non-epithelioid 1.40 0.80–2.45
SPARC
Low Reference
0.050
High 1.55 1.00–2.42
Abbreviations: CI, confidence interval; HR, hazard ratio; SPARC, secreted protein acidic and
rich in cysteine.
SPARC in mesothelioma BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2015.470 527
Circulating SPARC is likely secreted from the stroma of MPM
tumours. To investigate whether tumour or stromal cells are the
source of circulating SPARC, we evaluated cellular and secreted
SPARC levels in vitro. We found that cellular SPARC expression
was higher in 5 out of 7 cell lines than in the two immortalised
mesothelial lines (Figure 3). An association between histological
subtype and cellular SPARC was not evident. Assessment of
SPARC levels in cell-conditioned medium revealed a lack of
secreted SPARC in all cell lines (Figure 3). This finding was
mirrored by the observation that human SPARC was not detectable
in the plasma or serum of MPM xenograft-bearing mice (Figure 3).
In contrast, in a parallel study using the same samples, we were
able to detect another secreted protein, Fibulin-3, in the cell-
conditioned medium of all cell lines and in the plasma of
xenograft-bearing mice (Kirschner et al, 2015). The lack of
secretion of SPARC by MPM cell lines suggests stromal cells
within the tumour, rather than the tumour cells themselves, are the
source of circulating SPARC.
100
80
60
40
20
0
100
80
60
60 110 220
40
40 50
20
20 30
0
0 10
1.0
0.8
0.6
0.4
0.2
0.0
Tu
m
o
u
r/n
or
m
a
l m
es
ot
he
lia
l
ce
lls
 s
co
re
 (%
)
Mesothelioma  Normal mesothelium
Mesothelioma  Normal mesothelium
St
ro
m
al
 s
co
re
 (%
)
Cu
m
u
la
tiv
e
 s
u
rv
iva
l
Overall survival (months)
50%
>50% 
>50% censored 
50% censored 
A
B
C
D
E
F
Figure 2. Immunohistochemical staining for SPARC. (A) Sarcomatoid histological subtype with high SPARC expression in tumour cells (arrows) and
stroma (arrowheads). (B) Epithelioid mesothelioma with high SPARC expression in tumour (arrows) and low SPARC expression in stromal cells
(arrowheads). (C) Epithelioid mesothelioma with low SPARC expression in tumour (arrows) and low SPARC expression in stromal cells (arrowheads).
SPARC immunohistochemistry scores for mesothelioma compared with normal pleural mesothelium are shown in (D) tumour cells and (E) stromal
fibroblasts. Kaplan–Meier curve for patients undergoing P/D according to stromal SPARC is shown in (F).
Table 3. Association of SPARC protein expression and patient characteristics in the P/D patients (series three)
Stromal SPARC-high (450%) Presence of tumoral SPARC (100%)
Factors Groups Yes No % Yes P-value Yes No % Yes P-value
Age (years) o60 5 14 26
0.03
18 3 86
0.24
X60 28 22 56 36 15 71
Gender Male 28 27 51
0.38
40 18 69
0.02
Female 5 9 36 14 0 100
Histo-subtype Epithelioid 9 27 25
o0.001
27 9 75
1.00
Non-epithelioid 24 9 73 27 9 75
Abbreviations: P/D, pleurectomy±decortication; SPARC, secreted protein acidic and rich in cysteine.
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DISCUSSION
Our initial exploratory study demonstrated the feasibility of using
iTRAQ proteomic techniques to investigate potential prognostic
protein biomarkers in plasma of MPM patients. With this
methodology, we have shown that it is possible to identify candidate
plasma proteins with potential clinical significance, even in a
relatively rare disease such as MPM. We used iTRAQ initially as a
profiling tool to determine whether there were differentially
expressed proteins between the two groups of 12 patients divided
by their survival. We observed a good separation between the
samples from long and short survivors when restricting our analysis
to the five proteins identified as differentially expressed: SPARC,
selenoprotein P, tetranectin, IBP2 and CXCL7. We then proceeded
to quantify the selected protein levels by ELISA, which is often
considered as the gold standard in protein quantification. We found
high plasma levels of SPARC remained associated with short
survival. This finding was consistent in the iTRAQ and ELISA
experiments involving the 12 plasma samples of MPM patients, thus
making this protein the most promising candidate biomarker in our
exploratory study. To confirm this hypothesis-generating finding
from our Australian patient cohort, we assessed serum SPARC
concentrations using ELISA in an independent cohort of MPM
patients from the Netherlands. We confirmed the prognostic value
of circulating SPARC, adjusting for known prognostic factors such
as age, gender, stage and histological subtypes.
While promising, our study is limited by its retrospective nature
and the non-randomised allocation of treatment groups. Never-
theless, SPARC emerged as the most robust prognostic biomarker,
given that the direction of prognostication was consistent between
iTRAQ and ELISA in the discovery series as well as the
demonstration of the independent prognostic value in the
validation series. Further independent validation, preferably in a
prospective study, is needed to confirm the prognostic value of
circulating SPARC in MPM patients. A particular strength of our
study is that it adheres to the REMARK guidelines where
applicable, and uses pre-specified methods and analyses. Although
a retrospective study, the characteristics of the study patients, the
treatments received and the type of biological materials used and
method of preservation and storage are clearly described. Most
importantly, the multivariate model examining the independent
significance of circulating SPARC in the Dutch series (our primary
analysis) was fit to variables significant in the univariate analysis
(SPARC and gender) as well as commonly accepted standard
prognostic factors (age, histological subtype and stage), consistent
with item 17 of the REMARK guidelines (McShane et al, 2005).
SPARC belongs to a group of non-structural components of the
extracellular matrix that modulate interactions between cells and
their environment (Tai and Tang, 2008), and is considered to be
solely produced by the cancer-associated fibroblasts within
tumours (Chlenski et al, 2006). Secreted protein acidic and rich
in cysteine is known to be involved in regulating cell adhesion,
proliferation, migration and tissue modelling; and it interferes with
the binding of growth factors to their receptors in endothelial cells,
resulting in inhibited proliferation (Hasselaar and Sage, 1992;
Paulsson and Micke, 2014). Although SPARC expression is altered
in many solid tumours, its role in tumorigenesis appears to be cell-
type specific due to the diverse functions of SPARC within the
microenvironment of a given tumour (Chlenski and Cohn, 2010).
In some types of cancer, such as melanoma, glioma, colorectal,
osteosarcoma and gastric cancer, increased SPARC expression has
been shown to be associated with disease progression and poor
prognosis (Tai and Tang, 2008; Wang et al, 2014). which is
consistent with our findings in MPM. In others, such as ovarian
cancer, SPARC functions as a tumour suppressor with high levels
correlating with good prognosis (Tai and Tang, 2008). However,
there are inconsistent findings in the literature even within the
same tumour type. For example, in non-small cell lung cancer,
total SPARC expression (combined stromal and tumoral staining)
correlated with unfavourable patient outcome (Koukourakis et al,
2003), while another study showed stromal SPARC expression to
be associated with long patient survival (Huang et al, 2012), and a
third study found no prognostic impact of stromal SPARC
expression at all (Edlund et al, 2012).
Previous studies investigating the role of SPARC in cancer have
examined the SPARC expression in tumour, either by IHC or by
RT-qPCR, given its known biological function. As far as we know,
this is the first report in the literature to demonstrate the
prognostic importance of circulating SPARC in MPM patients.
Given the detectable levels of circulating SPARC and demonstra-
tion of its prognostic significance, we hypothesised that the source
of the circulating SPARC in our patients is the tumour itself. To
that end, we showed that SPARC is present in both the tumour
cells themselves and in the stromal components of the tumour with
variable staining in the fibroblasts. Our demonstration that SPARC
is expressed in both the tumour cells and stromal compartment is
consistent with the expression of SPARC in both the epithelium
and stroma of the prostate (Orr et al, 2012). Furthermore, we
observed increased SPARC expression in MPM compared with
normal mesothelial controls, suggesting a role for SPARC in the
pathogenesis of MPM.
Interestingly, we found abundant SPARC in the lysates of most of
the MPM cell lines, but none was secreted into the medium. This
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Figure 3. SPARC concentration measured by ELISA (ng per mg total protein) in cell lysates, cell-conditioned medium and mouse plasma/serum.
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finding is consistent with a previous study, which showed that
although both pancreatic cancer-derived fibroblasts and pancreatic
cancer cell lines expressed SPARC, only the fibroblasts secreted
SPARC in large quantities (Sato et al, 2003). One explanation for this
observation could be related to the recent finding that the
intracellular acidification frequently observed in cancer cells was
able to reduce the secretion of SPARC and other extracellular matrix
proteins by melanoma cells (Bellenghi et al, 2015). As human SPARC
was not detectable in the serum or plasma of MPM xenograft-bearing
mice, it further argues for a stromal origin for the SPARC detected in
patient serum. Nevertheless, although our in vitro and in vivo
experiments suggest that circulating SPARC is secreted from the
stromal fibroblasts rather than the tumour cells, other cell types could
be the source of SPARC, such as tumour-associated macrophages
(Sangaletti et al, 2008). Further studies are required to definitively
identify the origin of SPARC in patient serum.
In our current study, we did not examine the mechanism of
SPARC upregulation in MPM compared with normal mesothe-
lium. In glioma, miR-145 is downregulated, leading to increased
expression of connective tissue growth factor (CTGF), which in
turn leads to upregulation of SPARC (Lee et al, 2013). In MPM, it
has been reported that CTGF is upregulated in rat sarcomatoid
MPM (Jiang et al, 2014), and miR-145 is lower in MPM tumours
and cell lines compared with normal tissues (Cioce et al, 2014).
Therefore, we hypothesise that decreased miR-145 in MPM could
in turn lead to increased CTGF and upregulated SPARC.
Examination of the functional role of SPARC in MPM was also
beyond the scope of the current study. However, in gastric cancer
where in line with our findings, there is a high SPARC expression in
tumour and its expression is associated with poor prognosis,
preclinical work has demonstrated that downregulation of SPARC
inhibits invasion and growth of human gastric cancer cells (Yin et al,
2010). This is the subject of further study in our group.
Prognostication in MPM is important given the heterogeneity of
the tumour biology. If accurate prognostic stratification indicates a
short time to death, then either palliative therapy or best supportive
care alone may be appropriate; while a more aggressive approach to
therapy may be offered if long survival is indicated. In addition to
being a prognostic biomarker, SPARC may also be a potential
predictive biomarker for chemotherapy sensitivity. There is an
emerging association between tumoral and stromal SPARC and
pancreatic adenocarcinoma (Neuzillet et al, 2013). Secreted protein
acidic and rich in cysteine is overexpressed in the stroma of
pancreatic cancer and has been investigated as a target for nab-
paclitaxel. Nab-paclitaxel is a solvent-free, albumin-bound form of
paclitaxel, which is an anti-microtubule agent used to treat a number
of cancers. It has been shown that SPARC acts as a high-affinity
receptor for albumin, resulting in increased intratumoral uptake of
the drug. In a phase I/II study evaluating gemcitabine plus nab-
paclitaxel in pancreatic adenocarcinoma, stromal SPARC expression
was associated with improved OS, indicating that it may be a useful
predictive biomarker for response to nab-paclitaxel-based regimen
(Von Hoff et al, 2011). In a retrospective review of the SPARC
expression in patients from the CONKO-001 study (randomised
phase III study investigating the role of adjuvant gemcitabine vs
observation in resected pancreatic cancer), authors found that the
negative prognostic impact was only restricted to patients who
received adjuvant gemcitabine. This would suggest that SPARC is a
predictive marker for response to gemcitabine, which is a
chemotherapeutic agent commonly used in MPM (Sinn et al,
2014). Therefore, we believe that further clinical studies examining
the predictive value of stromal SPARC expression in MPM patients
undergoing gemcitabine or nab-paclitaxel would be worthwhile.
In conclusion, we have demonstrated that it is feasible to use
well-validated proteomic methods to explore potential biomarkers
in the plasma of MPM patients and showed SPARC to be a
promising circulating prognostic biomarker. Furthermore, we
validated the independent prognostic importance of circulating
SPARC in a large retrospective series of MPM patients. While
promising, this finding should be confirmed in a prospective
manner before it could potentially be used clinically. We also
demonstrated the presence of SPARC protein in the MPM tumour
cells as well as the stromal fibroblasts, with our results indicating
the stroma as the likely source of the circulating SPARC. We
believe that our findings indicate the potential biological
importance of SPARC in MPM and further studies examining
the function of SPARC in MPM are warranted.
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